NanoTechnology Solutions

PreciPoint manufactures solutions for the digitization of microscopy and laboratory processes for applications in medicine, research, and teaching. Its offerings include digital microscopes & scanners, services, and microscopy software. The company was founded in 2018 and is based in Freising, Germany.

MediSpectra, Inc. is a medical device company developing optical detection technology for enhanced accuracy and real-time results in the detection of cancer and other human tissue abnormalities. The technology is based on multimodal optical interrogation of tissue with light. Specifically, a combination of native fluorescence and white light backscatter spectroscopies are coupled with video imaging methods to more accurately detect tissue abnormalities. nnThe company's first product, the LUMA Cervical Imaging System, was designed and developed to improve the detection of high-grade pre-cancerous cervical abnormalities that have the potential of becoming invasive cancer. The LUMA product is intended for use as an adjunct to colposcopy in identifying high grade disease (CIN 2/3+) in patients referred to colposcopy with an ASCUS, LSIL or HSIL+ cervical cytology test result. n

Stage I Diagnostics is a cancer biotechnology company focused on providing early stage diagnosis provided by new biomarkers deployed through In-Vitro Diagnostics (IVD). The company's initial focus is the early diagnosis of ovarian cancer. Stage I's core competency is the process of converting newly discovered genes into commercial products which impact clinical decisions. The company's approach is to determine what characteristics new biomarkers should have to achieve the best diagnostic results in targeted diseases and then to discover what genes exist that fit those characteristics. This process has led us to not only discover and patent numerous genes associated with various types of cancer but also clone 4 new genes.

Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.

Microwave Imaging Systems Technology was founded in 1995 by Dr. Keith Paulsen and Dr. Paul Meaney of the Thayer School of Engineering and has developed a microwave-based, breast imaging system which aims to provide high-contrast images for breast cancer diagnostics. Per the company, the NIH has invested more than $6 million to develop and demonstrate the MIST system for tumor imaging. The company reports that testing on more than 150 patients has shown excellent detection of breast tumors.

a privately held, early stage medical device company focused on the development of imaging technology for biomedical use. The company is currently in stealth-mode and not disclosing the finer details of its technology until it secures necessary intellectual property rights. Spectral Image will initiate a pilot study of its technology at a premier medical facilities in 2008.